<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131247</url>
  </required_header>
  <id_info>
    <org_study_id>NVCI 09-15</org_study_id>
    <secondary_id>18083/6265</secondary_id>
    <nct_id>NCT01131247</nct_id>
  </id_info>
  <brief_title>PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine &amp; Ofatumumab</brief_title>
  <official_title>PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nevada Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nevada Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigational Drugs:&#xD;
&#xD;
      Ofatumumab (Azerra) + bendamustine (Trenda)&#xD;
&#xD;
      Route of Administration:&#xD;
&#xD;
      Intravenous (IV)&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      This study is designed to assess the toxicity and overall response rate. Ofatumumab is a&#xD;
      fully human monoclonal antibody (A type of protein made in the laboratory that can bind to&#xD;
      substances in the body, including tumor cells) that shows promising activity in the treatment&#xD;
      of CLL as a single agent. It is thought that by combining it with Bendamustine, an FDA&#xD;
      approved treatment for CLL, the effect on CLL will be greater than if Ofatumumab is given&#xD;
      alone. Ofatumumab is FDA approved for the treatment of relapsed/refractory CLL.&#xD;
&#xD;
      Participation:&#xD;
&#xD;
      Approximately 37 relapsed/refractory CLL subjects will participate in this study over two&#xD;
      years.&#xD;
&#xD;
      Treatment Plan:&#xD;
&#xD;
      A maximum of 6 cycles of treatment will be allowed. During day 1 of cycle 1 ofatumumab IV&#xD;
      300mg will be administered. On day 1 of all cycles ofatumumab treatment will be followed by&#xD;
      bendamustine IV 90mg/m2. On day 2 of all cycles, bendamustine IV 90mg/m2 will be&#xD;
      administered. On day 3 of all cycles, neulasta SQ 6mg will be given. On day 8 of cycle 1 only&#xD;
      patients will receive ofatumumab IV 1000mg. During cycles 2 through 6 ofatumumab 1000mg will&#xD;
      be given on day 1 only.&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      Patients will be followed monthly for six months, then every three months for five years then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left institution&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate/ Efficacy</measure>
    <description>The primary objective for this trial is to evaluate the overall response rate (CR+PR) of bendamustine and ofatumumab in patients with relapsed/refractory CLL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation</measure>
    <description>The first secondary objective is to evaluate the toxicity of patients with relapsed/refractory CLL treated with bendamustine and ofatumumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <description>Other secondary objectives include: evaluating the complete response rate, progression-free survivial, overal survival and time to next therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Analysis</measure>
    <description>This study also aims to determine whether expression of of ZAP-70, CD38, IgVH status, and chromosomes, correlate with response rate, duration of response, and survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>ofatumumab + bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofatumumab + bendamustine</intervention_name>
    <description>Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.</description>
    <arm_group_label>ofatumumab + bendamustine</arm_group_label>
    <other_name>Ofatumumab / Brand: Arzerra</other_name>
    <other_name>Bendamustine / Brand: Treanda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be &gt;/= 18 years old and able to provide consent&#xD;
&#xD;
          -  Must have diagnosis of CLL as defined by NCI criteria&#xD;
&#xD;
          -  Must require chemotherapy&#xD;
&#xD;
          -  Must be previously treated with a minimum of one course of prior chemo or other&#xD;
             treatment&#xD;
&#xD;
          -  Serum creatinine &lt;1.8 mg/dl&#xD;
&#xD;
          -  Bilirubin must be &lt;/= 2 mg/d, unless secondary to tumor&#xD;
&#xD;
          -  Must have adequate liver function (as defined as &lt;2x ULN, unless related to CLL)&#xD;
&#xD;
          -  AST/ALT &lt;2x ULN&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  Women of child bearing age must be willing to use accepted/effective method of birth&#xD;
             control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.&#xD;
&#xD;
          -  Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia&#xD;
&#xD;
          -  Not have history of corticosteroid treatment for CLL&#xD;
&#xD;
          -  Not have CNS disease&#xD;
&#xD;
          -  Not have clinically significant infections&#xD;
&#xD;
          -  Patients with a second malignancy, other than basal cell carcinoma of the skin or in&#xD;
             situ carcinoma of the cervix are not eligible.&#xD;
&#xD;
          -  Not have positive serology for Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Not have be known to be HIV positive&#xD;
&#xD;
          -  Not have New York Classification III or IV hear disease&#xD;
&#xD;
        Other protocol specific criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kirschbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nevada Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Leis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>PHoenix/Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nevadacancerinstitute.org/</url>
    <description>Visit Nevada Cancer Institute Website for more information on investigator or trial</description>
  </link>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark Kirschbaum, MD</name_title>
    <organization>Nevada Cancer Institute</organization>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>bendamustine</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>blood cancer</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>lymphocyte</keyword>
  <keyword>refractory</keyword>
  <keyword>Advanced</keyword>
  <keyword>relapsed</keyword>
  <keyword>hematologic</keyword>
  <keyword>hematology</keyword>
  <keyword>antibody</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>nevada cancer institute</keyword>
  <keyword>cephalon</keyword>
  <keyword>Glaxosmithkline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

